TriClip offers a remarkably safe, minimally invasive treatment option for patients in need of tricuspid valve repair but who are unable to withstand surgery
New leadership team announced at NATHEALTH Annual General Meeting 2024
The facility will manufacture tablets, capsules, and injections for the oncology segment
This partnership combines Tata Elxsi's design and technology expertise along with Dräger's expertise in medical and safety technology
First and only long-acting C5 complement inhibitor offers patients with AQP4 Ab+
More than 10,000 scientific publications containing EUDRAGIT
CRESEMBA receives seven years and six months of US market exclusivity for these pediatric indications
Pfizer to discuss regulatory submission with FDA, potentially leading to eighth indication for ADCETRIS
The WHO GMP approved vertically integrated ONCOLOGY unit of SAKAR has been selling products nationally since few quarters
The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD) Neurontin Tablets, 600 mg and 800 mg, of Viatris Specialty
Subscribe To Our Newsletter & Stay Updated
